Division of General Internal Medicine, Massachusetts General Hospital, 100 Cambridge St., Suite 1600, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
University of Maryland, School of Social Work, 525 W Redwood St, Baltimore, MD 20201, USA.
Drug Alcohol Depend. 2024 Oct 1;263:111419. doi: 10.1016/j.drugalcdep.2024.111419. Epub 2024 Aug 15.
Injecting, smoking, and snorting heroin/synthetic opioids is each associated with unique health risks. It is unclear how route of administration (ROA) preferences have shifted during the opioid epidemic.
Using 2000-2021 admissions data from SAMHSA TEDS-A, we analyzed trends in heroin/synthetic opioid ROA preferences and factors associated with these preferences.
7,881,318 heroin/synthetic opioid admissions reported injection, smoking, or snorting preference. Nationally, injection peaked in 2014 (69.9 %) and nadired in 2021(52.2 %), snorting nadired in 2014 (24.9 %) and peaked in 2021 (36.4 %), and smoking rose steadily from 2.5 % in 2005 to a peak of 11.4 % in 2021. From 2000-2021, the number of states with ≥10 % smoking rates grew from 2 to 27 (highest: 57.0 % in Arizona in 2021). In 2021, increased adjusted prevalence ratios (APR) of non-injection versus injection use were associated with older age at first opioid use (APR 1.52 [95 % CI: 1.51, 1.54] for those 30+ relative to ≤20), and all race/ethnicities relative to non-Latino White individuals (highest: Black individuals, APR 1.77 [1.75, 1.78]). Geography strongly predicted smoking versus snorting (Mountain APR 6.91 [6.64, 7.19], Pacific APR 6.61 [6.35, 6.88], reference: New England).
ROA preferences of heroin/synthetic opioids have changed substantially since 2000, with: 1) recent decreases in injection nationally; 2) increased smoking, particularly in the western US; and, 3) recent increased snorting in the eastern US. Smoking is now prevalent and growing. Public health implications include an increasing number of smoking-related fatal overdoses and the probable reduction of injection-specific morbidity and increase in smoking-specific morbidity.
注射、吸食和鼻吸海洛因/合成阿片类药物各自都与独特的健康风险相关。在阿片类药物流行期间,给药途径(ROA)偏好如何变化尚不清楚。
利用 SAMHSA TEDS-A 2000-2021 年的入院数据,我们分析了海洛因/合成阿片类药物 ROA 偏好的趋势以及与这些偏好相关的因素。
7881318 例海洛因/合成阿片类药物入院患者报告了注射、吸食或鼻吸偏好。在全国范围内,注射的使用率在 2014 年达到峰值(69.9%),在 2021 年降至最低点(52.2%),鼻吸的使用率在 2014 年达到峰值(24.9%),在 2021 年降至最低点(36.4%),而吸烟率则从 2005 年的 2.5%稳步上升至 2021 年的 11.4%。自 2000 年至 2021 年,至少有 10%的州吸烟率达到或超过 10%的州数从 2 个增加到 27 个(最高:2021 年亚利桑那州为 57.0%)。2021 年,与注射相比,非注射使用的调整后流行率比值(APR)增加与首次使用阿片类药物的年龄较大有关(与 20 岁以下的人相比,30 岁及以上的人,APR 为 1.52[95%CI:1.51, 1.54]),并且所有种族/族裔的 APR 都高于非拉丁裔白人(最高:黑人,APR 为 1.77[1.75, 1.78])。地理位置强烈预测了吸烟与鼻吸的差异(山区,APR 为 6.91[6.64, 7.19];太平洋地区,APR 为 6.61[6.35, 6.88];参考:新英格兰地区)。
自 2000 年以来,海洛因/合成阿片类药物的 ROA 偏好发生了重大变化,具体包括:1)全国范围内注射使用率的近期下降;2)吸烟率的增加,尤其是在美国西部;3)美国东部地区近期鼻吸使用率的增加。吸烟率现在已经很普遍并且还在增长。这对公共卫生产生了影响,包括与吸烟相关的致命过量用药的数量增加,以及可能减少与注射相关的发病率和增加与吸烟相关的发病率。